These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 1975737)

  • 21. Pharmacological and biochemical actions of sulphasalazine.
    Hoult JR
    Drugs; 1986; 32 Suppl 1():18-26. PubMed ID: 2877850
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reversible male infertility due to sulphasalazine: studies in man and rat.
    O'Moráin C; Smethurst P; Doré CJ; Levi AJ
    Gut; 1984 Oct; 25(10):1078-84. PubMed ID: 6148293
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Increased suppressor cell activity in inflammatory bowel disease.
    Holdstock G; Chastenay BF; Krawitt EL
    Gut; 1981 Dec; 22(12):1025-30. PubMed ID: 6119275
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sulphasalazine, sulphapyridine or 5-aminosalicylic acid--which is the active moiety in rheumatoid arthritis?
    Bird HA
    Br J Rheumatol; 1995 Nov; 34 Suppl 2():16-9. PubMed ID: 8535642
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A study to determine the active moiety of sulphasalazine in rheumatoid arthritis.
    Neumann VC; Taggart AJ; Le Gallez P; Astbury C; Hill J; Bird HA
    J Rheumatol; 1986 Apr; 13(2):285-7. PubMed ID: 2873245
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibition of leucocyte motility by drugs used in ulcerative colitis.
    Rhodes JM; Bartholomew TC; Jewell DP
    Gut; 1981 Aug; 22(8):642-7. PubMed ID: 6116649
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of the effect of oral sulphasalazine, sulphapyridine and 5-amino-salicylic acid on the in vivo antibody response to oral and systemic antigen.
    Sheldon P; Pell P
    Br J Clin Pharmacol; 1993 Mar; 35(3):261-4. PubMed ID: 8097101
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics of Upadacitinib in Healthy Subjects and Subjects With Rheumatoid Arthritis, Crohn's Disease, Ulcerative Colitis, or Atopic Dermatitis: Population Analyses of Phase 1 and 2 Clinical Trials.
    Nader A; Stodtmann S; Friedel A; Mohamed MF; Othman AA
    J Clin Pharmacol; 2020 Apr; 60(4):528-539. PubMed ID: 31701537
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of white blood cell dyscrasias during sulphasalazine therapy of rheumatoid arthritis and inflammatory bowel disease.
    Capell HA; Pullar T; Hunter JA
    Drugs; 1986; 32 Suppl 1():44-8. PubMed ID: 2877852
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The disposition and metabolism of sulphasalazine (salicylazosulphapyridine) in man.
    Azadkhan AK; Truelove SC; Aronson JK
    Br J Clin Pharmacol; 1982 Apr; 13(4):523-8. PubMed ID: 6121576
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Individualized sulfasalazine treatment of ulcerative colitis and monitoring of patient compliance by determining sulfapyridine serum concentration].
    Klugmann HJ; Giehler B; Lohmann D; Schiedewitz W
    Gastroenterol J; 1990; 49(4):160-4. PubMed ID: 1970478
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Therapeutic efficacy of sulfasalazine and its metabolites in patients with ulcerative colitis and Crohn's disease.
    Klotz U; Maier K; Fischer C; Heinkel K
    N Engl J Med; 1980 Dec; 303(26):1499-502. PubMed ID: 6107853
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Co-trimoxazole in rheumatoid arthritis: a comparison with sulphapyridine.
    Astbury C; Hill J; Bird HA
    Ann Rheum Dis; 1988 Apr; 47(4):323-7. PubMed ID: 3284488
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Disposition of 5-aminosalicylic acid, the active metabolite of sulphasalazine, in man.
    Fischer C; Maier K; Stumpf E; von Gaisberg U; Klotz U
    Eur J Clin Pharmacol; 1983; 25(4):511-5. PubMed ID: 6140167
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sulphasalazine: a review of 40 years' experience.
    Watkinson G
    Drugs; 1986; 32 Suppl 1():1-11. PubMed ID: 2877847
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A comparison of serum concentrations of sulphasalazine and some of its metabolites after therapy by the oral or rectal route.
    Ashworth M; Arthur M; Turmer AD; Smith PR
    Pharmatherapeutica; 1984; 3(8):551-5. PubMed ID: 6142465
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Simple and simultaneous determination of sulphapyridine and acetylsulphapyridine in human serum by column-switching high-performance liquid chromatography.
    Teshima D; Hino B; Itoh Y; Oishi R
    J Clin Pharm Ther; 2002 Dec; 27(6):403-8. PubMed ID: 12472979
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition of cell mediated cytotoxicity by sulphasalazine: effect of in vivo treatment with 5-aminosalicylic acid and sulphasalazine on in vitro natural killer cell activity.
    Aparicio-Pagés MN; Verspaget HW; Hafkenscheid JC; Crama-Bohbouth GE; Peña AS; Weterman IT; Lamers HW
    Gut; 1990 Sep; 31(9):1030-2. PubMed ID: 1976576
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inflammatory bowel disease: the in vitro effect of sulphasalazine and other agents on prostaglandin synthesis by human rectal mucosa.
    Pacheco S; Hillier K; Smith CL
    Braz J Med Biol Res; 1987; 20(2):221-30. PubMed ID: 2891390
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibition of stress-induced gastric ulcers by sulphasalazine and its constituents (sulphapyridine and 5-aminosalicylic acid) in rats.
    Garg GP; Cho CH; Ogle CW
    Pharmacology; 1990; 40(6):318-24. PubMed ID: 1978355
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.